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Abstract 
Background: Histone acetylation and deacetylation seem processes involved in the pathogenesis of Ewing sarcoma 
(EwS). Here histone deacetylases (HDAC) class I were investigated.
Methods: Their role was determined using different inhibitors including TSA, Romidepsin, Entinostat and PCI-34051 
as well as CRISPR/Cas9 class I HDAC knockouts and HDAC RNAi. To analyze resulting changes microarray analysis, 
qRT-PCR, western blotting, Co-IP, proliferation, apoptosis, differentiation, invasion assays and xenograft-mouse models 
were used.
Results: Class I HDACs are constitutively expressed in EwS. Patients with high levels of individual class I HDAC expres-
sion show decreased overall survival. CRISPR/Cas9 class I HDAC knockout of individual HDACs such as HDAC1 and 
HDAC2 inhibited invasiveness, and blocked local tumor growth in xenograft mice. Microarray analysis demonstrated 
that treatment with individual HDAC inhibitors (HDACi) blocked an EWS-FLI1 specific expression profile, while Enti-
nostat in addition suppressed metastasis relevant genes. EwS cells demonstrated increased susceptibility to treatment 
with chemotherapeutics including Doxorubicin in the presence of HDACi. Furthermore, HDACi treatment mimicked 
RNAi of EZH2 in EwS. Treated cells showed diminished growth capacity, but an increased endothelial as well as neu-
ronal differentiation ability. HDACi synergizes with EED inhibitor (EEDi) in vitro and together inhibited tumor growth in 
xenograft mice. Co-IP experiments identified HDAC class I family members as part of a regulatory complex together 
with PRC2.
Conclusions: Class I HDAC proteins seem to be important mediators of the pathognomonic EWS-ETS-mediated 
transcription program in EwS and in combination therapy, co-treatment with HDACi is an interesting new treatment 
opportunity for this malignant disease.
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Background
Ewing sarcoma (EwS) is a highly malignant bone and 
soft tissue neoplasia in children and young adults with 
early metastasis to lung and bone [1]. EwS is defined by 
specific balanced chromosomal EWSR1/ETS translo-
cations giving rise to oncogenic chimeric proteins, the 
most common being EWS-FLI1 as a consequence of the 
t(11;22)(q24;q12) translocation [2–4]. Other contributing 
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somatic mutations involved in disease development were 
only observed at low frequency [5–9].
EWS-FLI1 expression leads to widespread epigenetic 
changes in promoters, enhancers, and super-enhancers. 
Such global alterations of histone H3K27-acetylation 
as well as H3K27-trimethylation associated with an 
altered HDAC activity seem a general feature of EwS 
[10, 11]. More than 10 years ago, we identified histone 
methyltransferase EZH2, part of the polycomb repres-
sor complex (PRC2), to be overexpressed in EwS. RNA 
interference of EZH2 revealed an EZH2-maintained, 
undifferentiated reversible, highly malignant, stemness 
phenotype in EwS [12, 13]. Interestingly, the effects of 
gene silencing after RNA interference of EZH2 were 
mimicked by treatment of EwS with different HDAC 
inhibitors including Trichostatin A (TSA) or Entinostat 
(MS-275) [12].
There are a number of major classes of HDAC inhibi-
tors including hydroxamic acid-based, cyclic tetra/dep-
sipeptides, amino-benzamide-based, and short-chain 
fatty acid-derived inhibitors [14]. Entinostat (MS-275), 
an HDAC1 and HDAC3 inhibitor, was the first amino-
benzamide-based HDAC inhibitor to enter clinical trials 
[15]. Subsequent data revealed a reasonable safety profile 
and promising efficacy in patients with leukemia, lym-
phoma, melanoma, prostate cancer, renal cancer, non-
small cell lung cancer, and breast cancer, either alone or 
in combination with other therapies [16–19].
Romidepsin (FK228), a natural product isolated from 
Chromobacterium violaceum, gained approval to treat 
both cutaneous T-cell lymphoma (CTCL) and periph-
eral T-cell lymphomas (PTCL) [14]. Modifications to the 
hydroxamic acid scaffold of this HDAC1 and HDAC2 
inhibitor resulted in the discovery and synthesis of PCI-
34051 a HDAC8 specific inhibitor, which induced apop-
tosis in T-cell lymphoma without increasing histone and 
a-tubulin acetylation [20].
All these more selective HDAC inhibitors mentioned, 
target a specific group of HDACs belonging to the class 
I HDAC family comprising HDAC1, 2, 3 and 8. They are 
ubiquitously expressed, localized predominantly to the 
nucleus and exhibit selective enzymatic activity toward 
histone substrates. HDAC1 and HDAC2 are almost 
identical and often together in repressive complexes 
such as the sin3, NuRD, CoResT and PRC2 complexes 
[21]. HDAC3 is expressed in distinct complexes such as 
the N-CoR–smRT complex, but no complex has been 
described for HDAC8 so far [22].
In EwS antitumor activity of Entinostat seems medi-
ated via DNA synthesis inhibition, cell cycle arrest, 
increases in the expression of p21, TGF-βRII, and c-myc, 
as well as the induction of apoptosis [23, 24]. Recently, 
it was shown that HDAC3 is a transcriptional target of 
EWS-FLI1 and that Entinostat inhibits growth via sup-
pressing a previously unexplored EWS-FLI1/HDAC3/
HSP90 signaling axis [25]. Welch et al. selected clinically 
utilized chemotherapy agents and active metabolites 
including HDAC inhibitor Romidepsin and the revers-
ible LSD1 inhibitor SP2509, both part of the nucleosome 
remodeling and deactylase (NuRD) co-repressor com-
plex, for tests in EwS cell lines. In two drug experiments, 
synergy was observed with several combinations, includ-
ing when SP2509 was paired with topoisomerase inhibi-
tors or Romidepsin [26].
In order to better understand the role of class I HDACs 
in the pathogenesis of the disease and to develop appro-
priate approaches for new therapies in EwS, different 
inhibitors such as TSA, Romidepsin, Entinostat and PCI-
34051 were applied, CRISPR/Cas9 class I HDAC knock-
outs and cells with inducible HDAC specific shRNAs 
were generated and their influence on gene expression 
and biological behavior was investigated.
Material and methods
Cell lines
EwS cell line A673 was obtained from ATCC (LGC 
Standards, Teddington, UK). SK-N-MC was purchased 
from the German collection of Microorganisms and Cell 
GmbH (Leibniz Institute DSMZ, Braunschweig, Ger-
many). EW7 cell line was kindly provided by O. Delattre 
(Institut Curie, Paris, France). CHLA-10 were derived 
from the COG Cell Line & Xenograft Repository (www. 
cogce ll. org). For lentiviral packaging production, HEK 
293 T cells were obtained from Dharmacon™ (Colo-
rado, USA). EwS cell lines were cultured in RPMI1640, 
including 10% heat-inactivated fetal bovine serum and 
antibiotics (all Life Technologies, Darmstadt, Germany). 
CHLA-10 cell line required IMDM, 20% heat-inactivated 
fetal bovine serum, antibiotics and 1% insulin (Life Tech-
nologies). Cells were maintained at 37 °C and 5%  CO2 in 
a humidified atmosphere. EwS cell lines were routinely 
checked for purity (e.g. EWS-FLI1 translocation product, 
surface antigen or HLA-phenotype) and Mycoplasma 
contamination (MycoAlertTM Mycoplasma Detection 
Kit, Lonza, Basel, Switzerland) as well as for identity by 
DNA profiling using 8 different and highly polymor-
phic short tandem repeat (STR) loci (DSMZ or Eurofins, 
Ebersberg, Germany).
Chemical compounds
HDAC inhibitors, TSA, Entinostat (MS-275), Romidep-
sin (FK228) and PCI-340510 as well as chemotherapeu-
tics Doxorubicin and Vincristine were from Selleckchem 
(Houston, TX 77014 USA). A-395 was from Sigma-
Aldrich (Munich, Germany). The compounds were dis-
solved in dimethylsulfoxide (DMSO) or DEPC-treated 
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 H2O, depending on the manufacturer’s instructions, and 
stored at − 20 °C.
CRISPR/Cas9 knockouts
CRISPR/Cas9 knockouts of HDAC1 and HDAC2 in 
EwS cell lines (SK-N-MC, EW7, CHLA-10) were gener-
ated using the lentiCas9-Blast vector (plasmid #52962; 
Addgene, Watertown, MA, USA) and lentiGuide-Puro 
(Addgene; plasmid #52963). The sgRNA sequence rec-
ommendations were used and synthesized from librar-
ies for optimized sgRNA: Brunello and Brie, designed 
to maximize Rule Set 2 scores and minimize off-target 
sites with high CFD scores [27]. For lentiviral packaging 
the Trans-Lentiviral Packaging Kit (ThermoFisher Scien-
tific, Braunschweig, Germany) was used according to the 
manufacturer’s instructions.
Lentivirus mediated inducible RNA interference
Doxycycline inducible gene knock downs of either 
HDAC3, HDAC8 or EWSR1-FLI1 was achieved by the 
use of pZIP-TRE3G-ZsGreen or cloning into pTRIP-
Zmir30 vector (see Supplementary Information, Addi-
tional file  1), respectively. pZIP-TRE3G-ZsGreen were 
used according to manufacturer’s instructions (shER-
WOOD UltramiR lentiviral inducible shRNA, bacterial 
glycerol stock) and obtained from BioCat GmbH (Hei-
delberg, Germany). For lentiviral packaging the 3rd Gen-
eration Packaging Mix & LentiFectin™ Combo Pack Kit 
(Applied Biological Materials, Richmond, Canada) was 
used corresponding to manufacturer’s assignments.
Microarray analysis
Biotinylated target cRNA was prepared as previously 
described [12]. A detailed protocol is available at www. 
affym etrix. com. Samples were hybridized to Affymetrix 
Human Gene 1.0 ST microarrays and analyzed by Affy-
metrix software expression console, version 1.1. For data 
analysis, robust multichip average (RMA) normalization 
was performed, including background correlation, quan-
tile normalization, and median polish summary method. 
The volcano plot was generated using R (version 3.4.4; 
https:// www.R- proje ct. org/). To calculate p-values and 
log2 fold changes, the genes were tested for differential 
expression between groups based on log2 expression 
values. Before testing, all probe set IDs without mapped 
gene symbol were removed. The remaining 21,946 genes 
were tested for differential expression using the moder-
ated t-statistic of the R package limma with default set-
ting s. For gene ontology analysis overlapping up- or 
downregulated genes were identified using the jvenn 
platform [28] and analyzed via the Metascape platform 
with standard settings for pathway enrichment using GO 
Biological Processes, KEGG Pathway, Canonical Pathway 
and Reactome Gene Sets databases [29]. Array data in 
this manuscript were submitted at Gene Expression 
Omnibus (GEO) database, https:// www. ncbi. nlm. nih. 
gov/ geo/ query/ acc. cgi? acc= GSE16 2789.
Proliferation assay
Cell proliferation was measured with an impedance-
based instrument system (xCELLigence, Roche/ACEA 
Biosciences, Basel, Switzerland) enabling label-free real 
time cell analysis. Briefly, 2-4 ×  104 cells were seeded 
into 96-wells with 200 μl culture media containing FBS 
and allowed to grow up to 150 h. Cellular impedance was 
measured periodically every 4 h (relative cell index) and 
HDACi, EEDi, chemotherapeutics or DMSO was added 
as indicated in the Results section.
For synergy evaluation 0.5-1 ×  104 cells were seeded 
into white, flat-bottom, 96-well plates (Corning). Twenty-
four hours later, doxorubicin and/or HDACi (FK228 or 
MS-275) were added, and viability was assessed after 
72 h. Cell viability was measured using CellTiter-Glo 
Luminescent Reagent according to the manufacturer’s 
protocol (Promega). Luminescence was measured on a 
Promega GlowMax-Multi Detection System. Synergistic 
interactions were evaluated using the package Synergy-
finder [30] (Package version 2.2.4, R version 4.0.3, RStu-
dio version 1.3.1093) according to the Bliss algorithm 
[31].
Colony forming assay
Cells were seeded in duplicate into a 35-mm plate at a 
density of 5 ×  103 cells per 1.5 ml methylcellulose-based 
media (R&D Systems, Minneapolis, MN, USA) accord-
ing to the manufacturer’s instructions and cultured for 
10-14 days at 37 °C/5%  CO2 in a humidified atmosphere.
In vitro invasion assay
To study cell invasion, the BioCoat™ Angiogenesis Sys-
tem: Endothelial Cell invasion was used (BD Biosciences, 
San Jose, CA, USA) according to the manufacturer’s 
instructions as described previously [32].
Co‑immunoprecipitation (Co‑IP)
For Co-IP cells were seeded at 6-10 ×  106 per cell cul-
ture dish and cultivated until 70% confluence. Cells were 
subsequently harvested and treated using the Universal 
Magnetic Co-IP Kit (Active motif, Carlsbad, USA). Elu-
ates were analyzed by western blotting.
Western blot analysis
For western blots 2 ×  106 cells were resuspended in 200 μl 
2x Laemmli Sample Buffer (0.125 M Tris HCl, 20% glyc-
erol, 4% SDS and 0.002% Bromphenol Blue). Lysates 
were homogenized through a 23 gauge needle and 
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denatured at 70 °C for 10 min. Between 18 and 25 μl of 
protein lysate was loaded on 12% SDS-PAGE and trans-
ferred onto a PVDF membrane (GE Healthcare Amer-
sham™ Hybond™). After incubation with the specific 
primary antibody (see Supplementary Information), the 
membranes were incubated with appropriate secondary 
peroxidase-conjugated antibodies. For detection ECL™ 
Prime Western Blotting System (GE Healthcare, Chicago, 
IL, USA) and the Gel Logic 1500 imaging system ana-
lyzed with Kodak Molecular Imaging Software (Version 
5.0) was used.
Animal model
Immune deficient  Rag2−/−γc−/− mice on a BALB/c back-
ground were obtained from the Central Institute for 
Experimental Animals (Kawasaki, Japan) and maintained 
in our animal facility under pathogen-free conditions in 
accordance with the institutional guidelines and approval 
by local authorities (55.2.1-54-5232-42-2016). Experi-
ments were performed in 6-20 week-old mice.
In vivo experiments
To examine in vivo tumorigenicity of HDAC1 or HDAC2 
CRISPR/Cas9 knockouts and their respective controls, 
2-3 ×  106 EwS cells were injected subcutaneously into 
immune deficient  Rag2−/−γc−/− mice and xenograft 
tumor growth was monitored. Mice were investigated 
daily, tumor xenografts were measured with digital cali-
pers, and tumor volume was calculated as (L x  W2) / 2, 
where L is length and W is width. At the experimental 
endpoints, determined by completion of treatment or 
attainment of tumor burden exceeding  1cm3, mice were 
humanely euthanized, tumors excised and characterized.
To examine therapeutic value of HDACi Romidepsin 
(FK228) and EEDi (A-395) in  vivo, 2-3 ×  106 EwS cells 
were injected subcutaneously into immune deficient 
 Rag2−/−γc−/− mice. Once tumor was palpable mice were 
divided randomly into four groups and treated either 
with 250 mg/kg body weight A-395, 2 mg/kg FK228 or 
A-395 in combination with FK228 or solvent controls. 
FK228 was administered intra peritoneal (i.p.) once per 
week, A-395 subcutaneous (s.c) twice a week for 4 weeks.
Histology
Histological analysis of tumor specimens was performed 
in five tumors per group. Tissues were fixed in 10% 
neutral-buffered formalin solution for minimally 48 h, 
dehydrated under standard conditions (Leica ASP300S, 
Wetzlar, Germany) and embedded in paraffin. Serial 
2 μm sections were prepared with a rotary microtome 
(HM355S, ThermoFisher Scientific, Waltham, USA) and 
subjected to histological and immunohistochemical anal-
ysis. Hematoxylin-Eosin (H.-E.) staining was performed 
on deparaffinized sections with Eosin and Mayer’s Hae-
malaun according to a standard protocol. Immunohis-
tochemistry was performed using a Bond RXm system 
(Leica, Wetzlar, Germany, all reagents from Leica) with 
a primary antibody against cleaved caspase 3 (clone 
ASP175, 1:150, Cell Signaling 9664). All slides were 
scanned with a high-throughput scanning system (AT2, 
Leica). The percentage of tumor area occupied by cleaved 
caspase 3 positive tumor cells and the average number 
of mitoses per 10 high power fields (MI) in tumor cells 
was evaluated in all sections by experienced pathologists 
(TG/KS), and representative images were taken using 
Aperio ImageScope × 64 (version 12.4.0.7018, Leica).
Statistical analysis
Data are mean ± SEM as indicated. Statistical analysis 
was performed by unpaired two-tailed Student’s t-test or 
log-rank test, using Prism7 (GraphPad, San Diego, CA, 
USA) or Excel (Microsoft, Redmond, WA, USA). P-val-
ues < 0.05 were considered statistically significant. Either 
exact p-values or *p < 0.05, **p < 0.005, ***p < 0.0005 were 
indicated. Volcano plots were drawn with the free soft-
ware environment R (http:// www.r- proje ct. org/).
Results
Expression of HDAC class I genes in EwS
Histone deacetylase (HDAC) class I genes HDAC1, 2, 3, 
and 8 are widely expressed in different pediatric sarco-
mas (Fig.  1a) and other pediatric and adult tumor enti-
ties (Additional  file  2: Fig. S1a). Interestingly, the local 
tumor site in EwS may influence its level of expression 
(Additional file  2: Fig. S1b). In EwS cell lines HDAC 
class I genes are well expressed, too (Fig. 1b). To analyze 
whether the oncogenic fusion protein EWS-FLI1 may 
influence HDAC class I gene expression in EwS, we inves-
tigated RNA interference-mediated EWS-FLI1 silenc-
ing and observed a significant suppression of HDAC 
class I expression levels in two different EwS cell lines 
while one (EW7) seemed less affected (Fig. 1c). However, 
overexpression of EWS-FLI1 in mesenchymal stem cells 
L87 and V54.2 [12] only resulted in an upregulation of 
HDAC3 and 8 (Additional file  2: Fig. S1c). Remarkably, 
we also observed with a varying degree of significance 
that the level of individual class I HDAC expression 
may be associated with event-free survival in EwS when 
analyzing a publicly available study set of 85 patients 
(GSE63157, Fig. 1d).
Influence of HDAC inhibitors on histone modification 
and expression profile
To further investigate the role of class I HDACs in EwS 
we first used individual HDAC inhibitors (HDACi) 
to determine their role in histone modifications and 
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Fig. 1 Expression of HDAC class I genes in EwS. a Gene expression profiles of HDAC class I genes HDAC1, HDAC2, HDAC3, HDAC8 on 27 EwS, 
11 osteosarcomas (OS), 5 rhabdomyosarcomas (RMS), 5 synovial sarcomas (SyS), and 25 samples of different normal tissue (NT). Patient RNA 
were hybridized onto Human Gene ST 1.0 arrays (Affymetrix; GSE45544, GSE73166) and compared to a published microarray study of normal 
tissue (GSE45544). b Expression of class I HDAC genes in different EwS cell lines determined by qRT-PCR. c Expression of HDAC class I genes are 
downregulated in EwS cell lines after transient shRNA transfection with EWS-FLi1 specific shRNA (see Materials and methods) measured by qRT-PCR. 
Control transfectants contained irrelevant shRNAs. Transfectants were treated with doxycycline for 72 h. d Low HDAC class I gene expression 
correlates with event-free survival: Kaplan-Meier estimates for event-free survival probability for HDAC class I gene expression, using the GSE63157 
study set (n = 85) and the amc onco-genomics software tool (https:// hgser ver1. amc. nl/ cgi- bin/ r2/ main. cgi)
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subsequently monitored their influence on the general 
expression profile in EwS cell lines. To assess global alter-
ations of histones (H3K9/14-acetylation, H3K27-acetyla-
tion, H3K27-trimethlation) in EwS cell lines, tumor cells 
were incubated for 17 h with different HDACi. Western 
blot analysis showed an increase of histone H3K27-
acetylation and H3K9/14-acetylation after HDACi treat-
ment in all cell lines (Fig.  2a). An even higher increase 
of the acetylation of H3K27 and H3K9/14 was observed 
after treatment with Entinostat (MS-275) or Romidepsin 
(FK228) in CHLA-10 and EW7 cells. In contrast, treat-
ment with PCI-34051 only resulted in some increase 
of H3K27ac in comparison to the control. As expected, 
no alterations of H3K27-trimethylation were seen after 
treatment with HDACi.
HDACi-induced changes in gene expression in EwS 
cells A673, CHLA-10, EW7 and SK-N-MC were inves-
tigated by microarray analysis. Differentially expressed 
genes averaged across the used EwS cell lines are visu-
alized in volcano plots after treatment with Romidep-
sin or Entinostat (Fig. 2b). Significant deregulated genes 
are depicted in red. Treatment with Romidepsin led to 
differential expression of 2312 genes, treatment with 
Entinostat led to differential expression of 475 genes, 
respectively. Differential expression analysis comparing 
four different HDACi at a fold change of ±2 identified 
390 up- and 86 downregulated genes (Fig. 2c). Principal 
component analysis demonstrated that the level of dif-
ferential gene expression, mediated by individual HDACi 
treatment, led to the strongest deregulation of the EwS 
expression profile using TSA and Romidepsin (Fig.  2d). 
Using venn diagram analysis the strongest overlap of 
deregulated genes was observed after TSA and Romidep-
sin treatment (Fig. 2e). Furthermore, gene set enrichment 
analysis (GSEA) enrichment plots of up- and downregu-
lated gene sets after individual HDACi treatment showed 
that both Entinostat and Romidepsin treatment induced 
gene sets important for differentiation and downregu-
lated gene sets important for an EwS specific expression 
profile. Entinostat in addition, reduced gene sets impor-
tant for metastasis. However, PCI-34051 deregulated 
lesser gene sets, but those important for cell growth and 
survival (Fig. 2f ).
The EwS specific inhibition of differentiation by class I 
HDACs poses the question whether treatment with Enti-
nostat or Romidepsin would increase the ability to induce 
differentiation of EwS cells. We could observe a clear 
increased formation of endothelial differentiation (Addi-
tional file 2: Fig. S2a) and enhanced expression of GAP43 
and GFAP as markers for neuronal differentiation (Addi-
tional file 2: Fig. S2b) after treatment with one of the two 
inhibitors.
Overall, these results demonstrate that e.g. more spe-
cific HDAC class I inhibitors such as Entinostat (MS-
275; HDAC1 and 3 inhibitor) and Romidepsin (FK228; 
HDAC1 and 2 inhibitor) strongly deregulate the EwS spe-
cific profile and induce differentiation, with Romidepsin 
showing comparable results to the pan HDACi TSA.
Influence of CRISPR/Cas9 HDAC knockouts on proliferation 
and invasiveness
HDACi usually inhibit a group of HDAC genes, even 
those more specific class I HDACi. To find out which role 
individual HDACs may play in the pathogenesis of EwS, 
the CRISPR/Cas9 method was used to selectively knock-
out HDAC1 or HDAC2 in different EwS cell lines. The 
detection of HDAC class I knockouts in EwS cell lines 
was done by western blot analysis (Fig. 3a). Proliferation 
with the xCELLigence system demonstrates a significant 
decreased proliferation ability of HDAC1 and HDAC2 
knockouts in EwS cell lines in comparison to their con-
trol (Fig. 3a).
To investigate whether a decreased growth rate of 
these HDAC knockouts also affect their phases of cell 
cycle we used flow cytometry. We observed extended 
G1 phases for HDAC1 knockouts, especially in SK-N-
MC, EW7 and less evident in CHLA-10 cells (Addi-
tional file  2: Fig. S3a). For HDAC2 knockouts we saw 
(See figure on next page.)
Fig. 2 Influence of HDAC inhibitors on histone modification and expression profile. a (top) WB analysis of H3K9/14 ac, H3K27ac, H3K27me3 after 
HDACi treatment or solvent control (DMSO) for 17 h of three different EwS lines. β-actin served as loading control. (bottom) a table of the optical 
density of the individual band signals is given as the quotient of the individual value and the control (ß-actin). Values > 1.8 are shown in bold. b 
Volcano plots of differentially expressed genes averaged across four EwS lines (A673, CHLA-10, EW7, SK-N-MC). Each plot shows fold changes of 
log2 expression values (log FC) and adjusted p-values obtained from differential expression analysis comparing cell lines treated with HDACi (FK228 
or MS-275, respectively) to solvent controls. Red, genes obtained adjusted p-value < 0.05 and absolute log FC > 1; blue, genes with adjusted p-value 
< 0.05 and absolute log FC ≤ 1; green, genes with adjusted p-value ≥0.05 and absolute log FC > 1; and in black, genes with adjusted p-value ≥0.05 
and absolute log FC ≤ 1. c Heat map of 476 genes, 2-fold differentially expressed after HDACi treatment in four different EwS lines. Each column 
represents one individual array (robust multichip average (RMA); GSE162785). Cells were treated with DMSO or HDACi for 17-30 h. d Principal 
Component Analysis (PCA) plot showing the Principal Components (PC) 1 to 3. A dot represents one sample of the four different EwS lines, each 
treated with four HDACi, respectively (FK228, MS-275, PCI-34051, TSA). Two replicates of each cell line are shown as controls. In each cluster, a large 
dot in the center represents the average. Both PCA plots depict the same data from different perspectives. e Shared genes differentially expressed 
after individual treatment with different HDACi in four EwS lines (see [18]; GSE162785), respectively. For Venn diagram, genes ±2-fold differentially 
expressed were selected for analysis (http:// bioin forma tics. psb. ugent. be/ webto ols/ Venn/). f GSEA enrichment plots of up- and downregulated 
gene sets after individual HDACi treatment. NES: normalized enrichment score. GSEA: http:// www. broad insti tute. org/ gsea/ index. jsp
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a tendency for an extended G2 phase in all three cell 
lines tested (Additional file 2: Fig. S3a). We also in some 
HDAC knockouts, especially in CHLA-10 and SK-
N-MC, saw an increase of sub G1, indicating a higher 
rate of apoptosis. This prompted us to use immunocy-
tochemistry of γ-H2AX for these HDAC1 and HDAC2 
knockouts and indeed the investigated EwS cell lines 
show significant more double-strand breaks than their 
controls (Additional file 2: Fig. S3b).
These findings correlate with results of the analy-
sis of anchorage-independent growth of CRISPR/Cas9 
knockouts of HDAC1 or HDAC2 which demonstrated 
their critical contribution to colony formation ability in 
EwS cells (Fig. 3b, c). Furthermore, in vitro invasiveness 
was similarly affected. HDAC1 and 2 knockouts had a 
Fig. 2 (See legend on previous page.)
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decreased potential for invasiveness as demonstrated by 
Matrigel assay (Fig. 3d).
To further investigate if individual HDACs may coun-
terbalance knockouts of the other we inspected individual 
class I HDAC expression in HDAC knockouts and their 
controls by western blot analysis. We clearly observed 
increased HDAC2, 3, and even 8 expression in HDAC1 
knockouts at the protein level indicating compensa-
tory mechanisms (Additional file 2: Fig. S4a, top). How-
ever, the results for HDAC2 knockouts were less clear, 
but there were some compensatory effects for HDAC3 
and 8, too (Additional file 2: Fig. S4a, bottom). In addi-
tion, microarray analysis of HDAC knockouts revealed 
less deregulated genes when compared to treatment of 
Fig. 3 Influence of CRISPR/Cas9 HDAC knockouts on proliferation and invasiveness. a Proliferation and Western blot analysis (insets) of one to three 
HDAC1 (top) or HDAC2 (bottom) CRISPR/Cas9 knockouts in EwS cell lines CHLA-10, EW7 and SK-N-MC in comparison to controls (Cas9) are shown. 
Protein levels of Western blot analysis were detected with antibodies against HDAC1 and HDAC2. β-actin antibodies served as loading control. 
Proliferation and cell impendence was measured by the xCELLigence assay every 4 h. Data are shown as mean ± SEM (hexaplicates/group; p-value 
< 0.0001). b and c Analysis of anchorage-independent colony formation in methylcellulose of EwS cell lines with CRISPR/Cas9 mediated knockout 
of HDAC1 or HDAC2. Macrographs show a representative experiment with CHLA-10 and SK-N-MC HDAC1 ko (b) or HDAC2 ko (c). The number of 
colonies in different CHLA-10 or SK-N-MC HDAC clones was summarized in two bar graphs. d Analysis of invasiveness through Matrigel of different 
HDAC1 and HDAC2 CRISPR/Cas9 knockouts. Left, representative micrographs of invasive HDAC2 knockout and control cells 48 h after incubation are 
shown. Right, quantitative results for two different EwS lines are shown. Data are mean ± SEM of two independent experiments
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EwS cells with HDACi Entinostat or Romidepsin. Again, 
this indicates compensatory mechanisms of other class 
I HDACs in these knockout cells (Additional file  2: Fig. 
S4b, c).
Various attempts to generate stable HDAC3 CRISPR/
Cas9 knockouts in EwS cell lines were not successful, sug-
gesting HDAC3 to be essential for survival; while sgRNAs 
used for HDAC8 CRISPR/Cas9 knockouts seemed not 
effective. Therefore, the role of HDAC3 and 8 was fur-
ther investigated by transduction with inducible shRNA 
constructs (Additional file 2: Fig. S5a). After downregu-
lation of HDAC3 or HDAC8 in EwS cell lines, prolifera-
tion assay showed only a slight difference in proliferation 
ability for HDAC3 knock downs (Additional file  2: Fig. 
S5b above) and even less difference for HDAC8 knock 
downs compared to their control (Additional file 2: Fig. 
S5b at the bottom left). However, HDAC8 downregula-
tion in SK-N-MC HDAC1 knockouts showed a stronger 
block of proliferation than HDAC1 knockouts without 
HDAC8 downregulation (Additional file 2: Fig. S5b at the 
bottom right). In addition, HDAC3 knock down resulted 
in reduced invasiveness of CHLA-10 cells while similar 
HDAC8 downregulation in SK-N-MC HDAC1 knock-
outs demonstrated a superior reduction in invasiveness 
than without HDAC8 downregulation (Additional file 2: 
Fig. S5c).
HDAC1 and HDAC2 increase local tumor growth in vivo
To assess whether HDAC1 or HDAC2 knockouts also 
show a reduced tumor formation ability in  vivo, local 
tumor growth of CRISPR/Cas9 knockouts of HDAC1 or 
HDAC2 in EwS cell lines EW7 and SK-N-MC was ana-
lyzed. In a xenograft mouse model HDAC1 and HDAC2 
knockouts demonstrated reduced local tumor growth in 
all cell lines (Fig. 4a; and CHLA-10, see Additional file 2: 
Fig. S5d), resembling their proliferation ability in  vitro 
(Fig.  3a). Immunohistochemistry of HDAC knockout 
tumors and their controls demonstrated an increased 
cleaved caspase 3 expression in some HDAC knockouts, 
irrespective whether HDAC1 or HDAC2 knockouts 
were monitored (Fig.  4b, c right). However, increased 
caspase 3 cleavage was not a general phenomenon in 
these knockout cells. In addition, analysis of the mitotic 
index revealed decreased mitosis for some knockouts 
in comparison to their controls (Fig. 4c left), but not for 
all of them. This argues for a mixture of events explain-
ing decreased tumor growth of HDAC1 and HDAC2 
knockouts.
HDAC inhibition increases susceptibility to first line 
chemotherapy
Results so far indicated that HDAC1, HDAC2 and in 
part HDAC3 are important mediators of the EwS typical 
expression profile and malignant phenotype. Neverthe-
less, monotherapy using HDACi so far was not proven 
successful in EwS [33]. Therefore, we asked, whether 
HDACi may increase susceptibility of EwS to other 
drugs. Doxorubicin and Vincristine are first line chemo-
therapeutic agents used in the antitumor therapy of EwS 
patients [34]. For Doxorubicin and HDACi combination 
therapy in comparison to Doxorubicin monotherapy, 
a significant increase in proliferation blockade and an 
increase in apoptosis was observed (Additional file 2: Fig. 
S6). Combination index analysis of the combined effect of 
these drugs on proliferation (see Material and methods) 
using the Bliss algorithm [30] revealed a good synergy 
score for all combinations tested (Fig. 5a). Furthermore, 
western blot analysis of cleaved caspase 3 and PARP 
expression in EwS cell lines treated with Doxorubicin and 
HDACi demonstrated a strong induction of apoptosis 
after receiving combined treatment (Fig. 5b).
Expression analysis after combined treatment of Enti-
nostat and Doxorubicin revealed increased pro-apoptotic 
gene expression, ubiquitin-mediated protein degradation 
and AKT signaling (Fig. 5c, d) combined with decreased 
S-phase activity and resistance to Doxorubicin (Fig.  5d, 
e).
Furthermore, HDAC1 knockouts in EwS cells CHLA-
10 and SK-N-MC are significantly more susceptible to 
chemotherapeutics such as Vincristine, than their con-
trol (Additional file 2: Fig. S7a top). But combined treat-
ment of parental EwS cells with HDACi Entinostat or 
Romidepsin in combination with Vincristine did not 
reveal synergistic treatment effects (Additional file 2: Fig. 
S7a, bottom). However, gene expression analysis after 
treatment with Romidepsin, Vincristine and a combina-
tion of both identified relevant gene up- and downregu-
lation only present in the combination therapy, such as 
decreased double strand break repair (Additional file  2: 
Fig. S7b).
Combined inhibition of PRC2 and class I HDAC synergize 
to block proliferation and tumor growth
Histone methyltransferase EZH2 together with SUZ12 
and EED are essential components of PRC2. Due to the 
findings that class I HDACi inhibits an EWS-FLI1 spe-
cific expression profile and knockouts of HDAC1 and 
HDAC2 blocks tumorigenicity, which is comparable 
to RNA interference of EZH2 [12], we tested whether 
combined treatment of HDACi together with PRC2 
blockade may synergize in  vivo and in  vitro. Here we 
chose to use an EED inhibitor (A-395) and combined it 
with Romidepsin. Proliferation assay of EwS cell lines 
CHLA-10, EW7 and SK-N-MC showed a significant inhi-
bition of proliferation after treatment with a combina-
tion of HDACi and EEDi, demonstrating superiority to 
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Fig. 4 HDAC1 or HDAC2 increases local tumor growth in vivo. Evaluation of tumorigenicity of CRISPR/Cas9 knockouts of HDAC1 or HDAC2 
and their controls (Cas9) in EwS cell lines EW7 and SK-N-MC. a Immune deficient  Rag2−/−γC
−/−mice were injected s.c. with 4 ×  106 EwS cells. 
Kaplan-Meier plots of individual experiments with four to six mice per group are shown. Log-rank test was used to test for differences in survival. b 
Tumors of sacrificed mice were analyzed for cleaved caspase 3 by immunohistochemistry. Representative results of EW7 and SK-N-MC tumors are 
shown (10x original magnification). c Left, the number of mitoses per 10 high power fields per tumor is given. Right, level of cleaved caspase 3 in 
EwS tumors. The percentage of cleaved caspase 3 positive cells in five fields per tumor is given
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Fig. 5 HDAC inhibitors increase susceptibility of EwS to first line chemotherapeutics. a Heatmaps showing excess over Bliss synergy scores for 
combination treatment of Doxorubicin with HDACi FK228 (left) or MS-275 (right) in CHLA-10 or SK-N-MC cells. Scores greater than 1 (shown in 
red) denote synergistic combinations, whereas scores less than 1 (shown in green) denote antagonistic combinations. Data represent 3 technical 
triplicates. b Western blot analysis of caspase 3 and PARP as a measure of apoptosis susceptibility after treatment with Doxorubicin and HDACi, 
either in combination or individually. CHLA-10 were treated for 36 h and SK-N-MC for 24 h. Tubulin was used as loading control. c Focused heat 
map of genes, ≥1.5-fold differentially expressed in EwS line EW7 after combined treatment with DMSO, HDACi and/or first line chemotherapeutics 
Doxorubicin or Vincristine for 17 h. Treatment with Doxorubicin or Vincristine and MS-275, respectively, are highlighted in red. Each column 
represents one individual array. Microarray data with their normalized fluorescent signal intensities were used (robust multichip average (RMA); 
GSE162785). d GSEA enrichment plots of up- and downregulated gene sets after combined treatment with MS-275 and Doxorubicin. NES: 
normalized enrichment score. GSEA: http:// www. broad insti tute. org/ gsea/ index. jsp. e GSEA leading-edge analysis of identified gene sets (C5_all, 
GO gene sets) downregulated after combined treatment with MS-275 and Doxorubicin. Set-to-set analysis shows a correlation between combined 
MS-275 and Doxorubicin treatment and downregulation of gene sets important for chromosomal regulation
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Fig. 6 Combined targeting of PRC2 and class I HDACs results in the inhibition of proliferation and tumor growth. a Proliferation analysis of EwS 
cell lines CHLA-10, EW7 and SK-N-MC treated with either A-395, FK228 or a combination of both. Cell impedance was measured every 4 h. Data are 
shown as mean ± SEM (hexaplicates/group; p-value < 0.0001). b In vivo antitumor efficacy of FK228 and A-395 as a single agent or in combination 
against tumor-bearing  Rag2−/−γC
−/−mice. 2 ×  106 CHLA-10 or SK-N-MC EwS cells were injected subcutaneously (s.c.) into mice. Once tumors were 
palpable mice were randomly allocated into four groups (5 mice/group) and treated with vehicle control (DMSO), A-395 (250 mg/kg, s.c. twice per 
week), FK228 (2 mg/kg, intraperitoneal (i.p.) once per week), or with A-395 in combination with FK228 for 4 weeks (p < 0.0001). c All tumors were 
analyzed for cleaved caspase 3 by immunohistochemistry. Representative results of CHLA-10 tumors are shown (10x original magnification). d Top, 
the level of cleaved caspase 3 in CHLA-10 and SK-N-MC derived tumors. The percentage of cleaved caspase 3 positive cells in five fields per tumor is 
given. Bottom, the number of mitoses per 10 high power fields per tumor is given. e Interaction analysis by Co-IP of PRC2 protein EED with HDAC1, 
and HDAC2. Co-IP for CHLA-10, EW7, and SK-N-MC cell lines using anti-EED antibodies. After Co-IP, proteins were analyzed by western blotting for 
HDAC1, 2, 3 and 8. GAPDH served as a loading control
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monotherapy (Fig. 6a). Combined inhibition of spheroid 
cell growth of EwS cell lines and an EwS PDX derived 
primary culture was similarly effective (Additional file 2: 
Fig. S7c). In addition, similar synergistic behavior of com-
bined therapy with HDACi and EEDi was also observed 
in vivo. Tumors of SK-N-MC or EW7 in xenograft mice 
showed a strong inhibition of local tumor growth after 
treatment with HDACi and EEDi (Fig. 6b). Of note, single 
high doses of EEDi were ineffective in vitro and in vivo 
(Fig. 6a, b).
Western blot analysis of apoptosis susceptibility after 
Romidepsin or Entinostat and/or A-395 treatment 
in  vitro demonstrated a significant caspase 3 and PARP 
cleavage only after combined treatment (Additional 
file  2: Fig. S8a), respectively. Furthermore, immunohis-
tochemistry of treated tumors and their controls also 
indicated an increased cleaved caspase 3 expression in 
treated tumors, irrespective whether CHLA-10 or SK-
N-MC tumors were analyzed (Fig. 6c, d top). Enhanced 
apoptosis seemed strongest after combined treatment, 
however, this was not statistically significant. Further-
more, analysis of the mitotic index revealed a tendency 
for decreased mitosis in SK-N-MC tumors after HDACi 
and/or EEDi treatment in comparison to their controls 
(Fig. 6d bottom).
Expression analysis of treated tumors identified a num-
ber of differentially expressed genes including decreased 
expression of pediatric cancer markers and EZH2 targets 
only after combined treatment (Additional file 2: Fig. S8b, 
c, d). Final Co-IP experiments in EwS cells confirmed an 
interaction of PRC2 together with HDAC1 and 2 in EW7 
and SK-N-MC cells, but not with HDAC3 and 8 (Fig. 6e).
Discussion
The expression of EWS-FLI1 in EwS leads to large-scale 
epigenetic alterations that result in global modifications 
of histone H3K27-acetylation as well as H3K27-trimeth-
ylation in conjunction with altered histone deacetylase 
(HDAC) activity [10, 11]. HDAC class I genes are strongly 
expressed in various pediatric sarcomas and other pedi-
atric and adult tumor entities. EwS are very susceptible 
to HDAC inhibition [12, 23–25]. The activity of e.g. Enti-
nostat in EwS seems to be mediated by the inhibition of 
DNA synthesis, cell cycle arrest, the increase of expres-
sion of p21, TGF-βRII and c-myc and the induction of 
apoptosis [23, 24]. Our western blot analyses revealed 
increased histone H3K27-acetylation and H3K9/14-
acetylation not only after treatment with the pan-HDACi 
TSA, but also with more class I specific HDACi Enti-
nostat (MS-275) or Romidepsin (FK228). However, 
treatment with PCI-34051 did not result in histone 
changes, suggesting that HDAC8 is not involved in these 
processes.
Subsequent gene expression analysis after individual 
class I specific HDACi treatment showed induction of 
genes important for cellular differentiation and a strong 
inhibition of EwS-specific expression profiles by Enti-
nostat or Romidepsin. PCI-34051 deregulated less indi-
vidual genes in EwS, but those important for cell growth 
and survival. These observations support previous results 
demonstrating that Romidepsin decreased EWS-FLI1 
mRNA levels [35], and that Romidepsin and Entinostat 
induced antiproliferative activity in EwS cells [24, 35].
In addition, individual treatment with either Entinostat 
or Romidepsin resulted not only in an increased expres-
sion of genes relevant for cellular differentiation, but 
also in an increased ability of EwS cells for endothelial 
or neuronal differentiation. These observations correlate 
with previous results demonstrating that class I HDAC 
support an EwS-specific malignant stemness expression 
profile [12]. This also partly explains our observation 
that a high individual class I HDAC expression correlate 
with poor prognosis in EwS patients. Similar results were 
observed in other tumor entities. Increased expression of 
HDAC1, 2 and 3 has been associated with poor outcome 
in gastric and ovarian cancer [36–38], while high HDAC8 
levels correlate with advanced disease and poor survival 
in neuroblastoma [39, 40].
Genetic analysis of the role of individual HDAC class 
I genes by CRISPR/Cas9 knockouts showed that both 
HDAC1 and 2 expression are essential for proliferation, 
invasiveness and local tumor growth of EwS cells. In 
addition, prolonged sub-G1 phases in cell cycle analysis 
in some HDAC1 and 2 knockouts as well as increased 
γ-H2AX signals, indicate an increased rate of apopto-
sis and significant increase of double-strand breaks, 
respectively.
Immunohistochemistry of EwS tumors revealed an 
increased expression of cleaved caspase 3 in some HDAC 
knockouts, regardless of whether HDAC1 or HDAC2 
knockouts were analyzed. This suggests that knockouts of 
these genes in EwS are associated with a certain cellular 
stress. This hypothesis is supported by the observation 
that especially in HDAC1 knockouts an increased expres-
sion of HDAC2, HDAC3 and even HDAC8 was observed 
in western blot analysis, indicating compensatory mecha-
nisms by other HDAC of this class. However, for HDAC2 
knockouts only low compensatory expression of other 
HDAC genes was witnessed. HDAC1 and 2 are often co-
expressed to jointly regulate many biological processes, 
such as DNA damage repair, cell cycle, autophagy and 
hematopoiesis [41]. Interestingly, depletion or inhibition 
of HDAC1 and 2 in primary or oncogene-transformed 
fibroblasts resulted in a senescence-like G1 cell cycle 
arrest, accompanied by upregulation of p21 and p53 [42].
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Our attempts to generate stable HDAC3 CRISPR/Cas9 
knockouts in EwS cell lines were not successful. We were 
only able to generate transient knockouts indicating that 
HDAC3 is essential for the survival of EwS cells. How-
ever, subsequent RNA interference analysis of the role of 
HDAC3 and 8 in EwS only revealed a small difference in 
proliferation ability for HDAC3 knock downs and even 
fewer differences for HDAC8 knock downs compared to 
their controls. Remarkably, HDAC8 downregulation in 
SK-N-MC HDAC1 knockouts demonstrated a stronger 
block of proliferation and reduction of invasiveness than 
without HDAC8 downregulation overall indicating addi-
tive effects in EwS when more than one HDAC member 
of this class is affected. HDAC3 and HDAC8 seem differ-
entially regulated, not only in EwS. While HDAC3 associ-
ates with other proteins than HDAC1 and 2, for HDAC8 
no protein complex has been described [22].
Our results suggest that HDAC1, 2 and partly HDAC3 
are important mediators of the EwS-typical expression 
profile and the malignant stemness phenotype. How-
ever, monotherapy with HDACi so far was not suc-
cessful. Generally, monotherapy with suberoylanilide 
hydroxamic acid (SAHA) an inhibitor of class I and II 
HDACs seems to be less effective in solid tumors [43]. In 
childhood cancer, phase I studies with SAHA alone and 
in combination with 13-cis-retinoic acid [44], Temozo-
lomide [45] or Bortezomib [46] have been completed. A 
recent phase I study with Entinostat as a monotherapy to 
determine dosage and safety is being evaluated in pedi-
atric patients with recurrent or refractory solid tumors 
(NCT02780804), including central nervous system 
(CNS) tumors and lymphomas, but not in EwS or other 
pediatric sarcoma patients. A study investigating SAHA 
together with backbone chemotherapy in pediatric 
patients with tumors including Ewing and rhabdomyo-
sarcoma is recruiting (NCT04308330).
First line chemotherapeutic agents used in antitumor 
therapy of EwS patients include Doxorubicin and Etopo-
side [34]. They are both topoisomerase II enzyme inhibi-
tors. SAHA antagonistically affected the antiproliferative 
effect of Doxorubicin in the majority Ewing sarcoma cells, 
but synergistically enhanced the antiproliferative activity 
of etoposide [33]. Here, HDACi treatment increased the 
susceptibility of EwS cells to Doxorubicin, irrespective 
whether suboptimal doses of Entinostat or Romidepsin 
were used. In combination suboptimal doses of Doxo-
rubicin and HDACi significantly blocked growth of EwS 
cells and increased apoptosis compared to Doxorubicin 
monotherapy. Expression analysis of such combined 
treatment with Entinostat and Doxorubicin revealed 
an increased pro-apoptotic gene expression, ubiquitin-
mediated protein degradation and AKT signaling in com-
bination with decreased S-phase activity and resistance 
to Doxorubicin. HDACs seem essential for heterochro-
matin formation [47]. When such formation is inhibited, 
DNA would be structurally less dense and more open to 
agents that damage DNA and increase nucleosome turn-
over such as the anthracycline Doxorubicin [48].
Another very interesting option for combination ther-
apy appeared a combination of HDACi with PRC2 inhibi-
tors. We had already observed that HDACi class I inhibit 
an EWS-FLI1-specific expression profile and that the 
elimination of HDAC1 and HDAC2 reduces the tumor 
susceptibility of EwS cells. Interestingly, the analysis of 
expression profiles after RNA interference of EZH2 and 
HDACi treatment with TSA showed very similar expres-
sion patterns [12]. Therefore, a combination of an EED 
inhibitor (A-395) [49] together with Romidepsin seemed 
reasonable. Suboptimal doses of both substances that 
were effective only in their combination, synergistically 
suppressed proliferation in  vitro as well as in  vivo and 
induced significant caspase 3 or PARP cleavage. This 
combination therapy was similarly effective in the sphe-
roid model of EwS cell lines and two primary cultures 
derived from EwS PDX. It is noteworthy that high doses 
of EEDi monotherapy had no effect on tumor prolif-
eration. Expression analysis of treated tumors identified 
decreased expression of pediatric cancer markers and 
EZH2 targets, only after combined treatment, supported 
by Co-IP experiments confirming an interaction of PRC2 
together with HDAC1 and 2 in EwS cells.
We had already observed in previous experiments that 
results after RNA interference of EZH2 [12] could not 
be reproduced with EZH2 inhibitors such as GSK126 or 
GSK343 (data not shown). An EED inhibitor appeared 
interesting because it not only suppressed EZH2 activ-
ity but also potentially inhibited the presence of PRC2 in 
chromatin [49]. The lack of effect of EZH2 inhibitors also 
suggested that HDACs interacting with PRC2 mediated 
the effects on the expression profile previously observed 
after RNA interference of EZH2 [12].
Conclusions
HDAC1 and HDAC2 are important mediators of the 
pathognomonic EWS-ETS-mediated transcription pro-
gram in EwS. Their knockout blocks proliferation, inva-
siveness and tumor growth in xenograft mice. Expression 
analyses of EwS cells demonstrated that treatment with 
individual HDACi blocked an EWS-FLI1-specific expres-
sion profile and increased susceptibility to treatment with 
first line chemotherapeutic agents such as Doxorubicin. 
Combination therapy of HDACi together with PRC2 
inhibitors like the EED inihibitor A-395, that interfere 
with chromatin binding of the PRC2/HDAC1/2 complex, 
significantly block tumor growth of EwS in a xenograft 
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mouse model and could be an interesting new treatment 
option for this malignant disease.
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